Know the risks before you start.

Nausea — Usually worst in first 2-4 weeks, improves with dose titration. Taking with a small meal helps.

Vomiting — More common with faster dose escalation. Slow titration reduces incidence significantly.

Diarrhea or constipation — GI system adapts over weeks. Adequate hydration and fiber help.

Decreased appetite — This is the intended mechanism, but can feel unpleasant initially.

Fatigue — Often related to reduced caloric intake rather than the peptide itself.

Injection site reactions — Redness, itching, or small bumps at injection sites. Rotating sites helps.

Headache — Usually mild and temporary in first 1-2 weeks.

Dizziness — May indicate inadequate food intake or dehydration.

Acid reflux/GERD — GLP-1s slow gastric emptying, which can worsen reflux in susceptible individuals.

Pancreatitis — Severe, persistent abdominal pain radiating to back. Stop immediately and get evaluated.

Gallbladder issues — Right upper quadrant pain, especially after fatty meals. Risk increases with rapid weight loss.

Severe hypoglycemia — If used with insulin or sulfonylureas. Symptoms: shaking, confusion, sweating.

Thyroid changes — GLP-1s carry warnings about thyroid C-cell tumors in rodent studies. Those with MEN2 or medullary thyroid cancer history should not use these compounds.

Nausea — Usually transient, more common with oral administration.

Dizziness — Occasional reports, mechanism unclear.

Headache — Mild, typically resolves with continued use.

Lethargy — Some users report temporary fatigue.

Skin flushing — Rare, may indicate vasodilation.

BPC-157 has been shown to promote angiogenesis (blood vessel formation). This is beneficial for healing but raises theoretical concerns about tumor growth in those with existing cancers — though no human evidence supports this risk.

Long-term safety data is absent. Most protocols run 4-8 weeks with breaks.

Flu-like symptoms — Some users report mild fatigue, aches in first few days. May reflect immune modulation.

Headache — Occasional, usually mild.

Temporary lethargy — Typically first 1-3 days of use.

Injection site irritation — Localized redness or itching.

Same angiogenesis considerations as BPC-157.

TB-500 affects cell migration and proliferation — theoretical (not proven) concerns about cancer growth in those with existing malignancies.

Water retention — Puffiness in face, hands, ankles. Usually dose-dependent and temporary.

Joint pain/stiffness — Related to water retention in joint spaces. Often worse initially.

Carpal tunnel symptoms — Numbness, tingling in hands, especially at night. Classic sign of GH elevation.

Increased hunger — GH stimulates appetite. May counteract weight loss goals if not managed.

Vivid dreams — Altered sleep architecture is common. Some find this positive, others disturbing.

Morning lethargy — GH pulses during sleep can cause grogginess on waking.

Longer half-life = sustained GH elevation = more pronounced side effects

More likely to cause water retention, joint issues

Flushing/warmth after injection (normal, from GHRH mechanism)

Generally best-tolerated GHRP

Minimal cortisol/prolactin increase (unlike GHRP-6)

Hunger increase less pronounced than other GHRPs

Occasional headache or dizziness

FDA-approved for HIV lipodystrophy, so actual safety data exists

Well-tolerated in clinical trials

Joint pain, swelling, injection site reactions most common

Contraindicated in pregnancy, pituitary disorders

Insulin resistance — Chronic GH elevation can impair glucose metabolism. Monitor fasting glucose.

Tumor growth risk — GH promotes cell proliferation. Avoid if cancer history exists.

Pituitary suppression — Prolonged use may affect natural GH production. Cycling helps.

Derived from GH but supposedly without GH's side effects

Limited clinical data; one study showed no significant safety issues

Reported: Headache, nausea, injection site reactions (all mild/infrequent)

Theoretical: Since it's a GH fragment, some metabolic effects possible

Failed to gain FDA approval — efficacy concerns, not safety issues

Naturally occurring peptide discovered in 2015

Very limited human data

Reported: Generally well-tolerated in small trials

May affect blood sugar regulation (monitor if diabetic)

Research ongoing — long-term safety unknown

Not a peptide but often grouped with them

Inhibits NNMT enzyme to increase NAD+ and promote fat metabolism

Very limited data — mostly animal studies

Reported: Generally well-tolerated

Long-term effects completely unknown

Oral administration, no injection site issues

Nausea — Very common (40%+ in trials). Often severe. Usually passes within hours.

Flushing — Warm sensation, facial redness. Normal mechanism response.

Headache — Common, usually mild to moderate.

Blood pressure changes — Transient increases reported. Caution if hypertensive.

Do not use within 24 hours of alcohol — increases nausea substantially.

Developed for tanning, also has sexual function effects

Nausea/flushing — Common, especially initial doses

Facial flushing — Distinct from overall flushing, often patchy

Appetite suppression — Significant in many users

Spontaneous erections — Common side effect in males

Darkening of moles — Concerning because it could mask melanoma changes

New moles/freckles — Long-term melanocyte stimulation

Serious concern: Increased melanoma risk is debated but biologically plausible. Dermatologist monitoring recommended for users.

Telomerase activator, anti-aging focus

Very limited data — mostly Russian studies from 1990s-2000s

Generally reported as well-tolerated

No major side effects documented, but sample sizes tiny

Long-term effects unknown

Often used topically for skin, sometimes injected

Topical: Generally well-tolerated, occasional irritation

Injected: Limited data, generally mild if any side effects

Copper accumulation is theoretical concern with long-term use